Actinium Pharmaceuticals, Inc. (ATNM) Financials

ATNM Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 45.4 million 43.1 million
Dec. 31, 2025 51.8 million 43.9 million
Sept. 30, 2025 56.2 million 42.4 million
June 30, 2025 63.0 million 44.0 million

ATNM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -5.9 million 11000
Dec. 31, 2025 -5.4 million 10000
Sept. 30, 2025 -6.3 million 109000
June 30, 2025 -5.4 million 197000

ATNM Net Income

No data available :(

ATNM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 42.1 million - 785000
Dec. 31, 2025 48.0 million - 972000
Sept. 30, 2025 53.4 million - 1.1 million
June 30, 2025 59.9 million - 690000

ATNM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 31.2 million
Dec. 31, 2025 31.2 million
Sept. 30, 2025 31.2 million
June 30, 2025 31.2 million

ATNM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2000 4.2 million 1.7 million -
Dec. 31, 2025 104000 4.9 million 2.1 million -
Sept. 30, 2025 - 4.2 million 1.5 million -
June 30, 2025 - 4.9 million 2.6 million -

ATNM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 220000
Dec. 31, 2025 - -615000
Sept. 30, 2025 90000 206000
June 30, 2025 - 204000

ATNM Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ATNM

Price: $0.89

52 week price:
0.89
1.89

Earnings Per Share: -0.76 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 219900

Market Capitalization: 32.3 million

Links: